Targeted Oncology· @TargetedOnc · X·· 22 小时前评分70
正文 · 机器翻译
ESMO 2026 主席研讨会 II 回顾：在肺癌和胃肠道癌症的 III 期 Krascendo 1、SAFFRON、CLARITY-Gastric01 和 HARMONi-GI1 试验中均报告了生存获益。#ESMO26
https://www.targetedonc.com/view/esmo-2026-savolitinib-presidential-symposium-divarasib-nsclc-krascendo1-saffron-clarity-gastric01-harmoni-gi1
25 浏览 · 0 赞 · 0 转发 · 0 回复
会议摘要
Krascendo 3: A randomised, phase III trial in progress of divarasib vs immunotherapy or observation in patients with resected, stage II-IIIB, KRAS G12C+ non-small cell lung cancer
https://esmocongress.esmo.orgKRASCENDO-1
https://esmocongress.esmo.orgKRASCENDO-1
https://esmocongress.esmo.org来源：Targeted Oncology · x.com